Focusing on innovative off-the-shelf immunotherapeutics, we turn to multispecific antibody xLinkTsAb platform to offer additional specificity for tumors or enhanced immune-cell activation. Our own property multispecific constructs permit to stimulate direct tumor killing by engaging cytotoxic T cells in a tumor antigen-dependent way.
xLinkTsAb T cell engager
- TA targeting with high selectivity
- Re-direct T cells to cancer cells
- Activate T cells only when TA is engaged
- Cross-linking dependent activity
- Dual signaling of CD3 and CD137
- Superior preclinical efficacy
- IgG like design; patent filed
Broad TA positive tumors in the clinic
- CD19, CD20, B7H3, DLL3, PSMA , other TA projects ongoing
Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines or platform technology. Please contact us to explore collaboration opportunities.
沪公网安备 31011502015346号